This is a non-interventional, study to assess demographic characteristics and patient reported outcomes in China patients with SEA treated with benralizumab

Trial Identifier: D3250R00131
Sponsor: AstraZeneca
Start Date: July 2025
Primary Completion Date: December 2026
Study Completion Date: December 2026
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Anhui, China
China Anning, China
China Beijing, China
China Binzhou, China
China Changzhou, China
China Fenyang, China
China Guangdong, China
China Guangzhou, China
China Hangzhou, China
China Huzhou, China
China Jiaxing, China
China Jinan, China
China Jinhua, China
China Jining, China
China Jiyuan, China
China Kunshan, China
China Linyi, China
China Mianyang, China
China Nanbu, China
China Nanchang, China
China Nanjing, China
China Ningbo, China
China Shanghai, China
China Shanxi, China
China Shenzhen, China
China Shijiazhuang, China
China Suining, China
China Taiyuan, China
China Weifang, China
China Wuhan, China
China Wuxi, China
China Xiamen, China
China XiAn, China
China Zhangjiagang, China
China Zhengzhou, China
China Zhenjiang, China